Dhan Chand, Vice President of Research at Agenus, shared a post on LinkedIn:
“Novel cell therapy combinations can deepen and extend the reach of immunotherapy.
At SITC2024 visit Poster 753 where Martyna Popis and Nils Rudqvist present AgenT-797, MiNK Therapeutics novel allogeneic iNKT cell therapy.
New data shows how AgenT-797 enhances checkpoint inhibitors and bispecific engagers to drive curative responses in challenging solid tumors.
This work represents an important step forward in expanding treatment options for cancer patients through innovative iNKT cell therapy combinations.
More posts featuring Dhan Chand.